Announcement PDF Immuron to Present at the RedChip Global Online Microcap Conference 22nd October, 2015 – Melbourne, Australia: Mr Thomas Liquard, CEO of Immuron Limited (ASX: IMC; OTC US: IMROY), is scheduled to present at the RedChip Global Online Microcap Conference on Thursday 22nd October, 2015, at 9:30AM US Eastern time. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation. Investors can pre-submit their questions by visiting http://www.redchip.com/events/3/global-online-microcap-conference. The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip’s microcap conference series each year. No registration is required to participate in the conference. Start times are subject to change. As previously announced, Immuron engaged Red Chip for the provision of certain US Investor Relations Services. On 20th August 2015 Red Chip released an Analyst Report which attracted significant online and market attention. A copy of this report is available at www.immuron.com/index.php/download_file//view/140/. Contact: Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 Email: thomasliquard@immuron.com Jon Cunningham RedChip Companies, Inc. US Tel: 0011 1-800-RED-CHIP (733-2447), ext. 107 Email: info@redchip.com About RedChip Companies, Inc. RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, “The RedChip Money Report: Small Stocks Big Money”™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. www.redchip.com Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143 www.immuron.com ABN: 80 063 114 045 Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735 COMPANY PRESENTATION October 2015 Forward-Looking Statement Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. 2 Corporate Overview • Unique and Leverageable Platform – Proprietary oral immunotherapy technology targeting microbiome and inflammation with broad utility • Attracting Leading Collaborations – NIH, Renowned experts and institutions • Strong Pipeline – High value indications, with leading competitive profiles • Phase II in NASH (Fatty-Liver Disease) - Targeted End of enrollment: 2Q16; Top Line results: 4Q16 – 1Q17 - Two unique inflammatory modulating mechanisms: (1) Binds to LPS, (2) Promotes regulatory T-Cell; Restores normal liver function and reverses fibrosis - No approved therapy, $40B market by 2025 • C-Difficile program targeting the 3 key infectious cycles (Toxin B, Spores, and Vegetative cells) in pre-clinical stage - Developed in collaboration with world renown C-difficile team at Monash - Phase 1/2 start anticipated in 1H2016 • Generating Growing Revenues – Travelan™ for Traveler’s Diarrhea • Significantly Undervalued – Substantial upside exist for investors 3 Investment Highlights Immuron Is a Compelling Investment Opportunity… NASH and ASH: Two Phase II studies in progress with an increasingly alluring potential upside Travelan: Revenues growing and positioned to grow further with successful USA launch Pipeline: Progressing; potential for multi-billion $ assets Cap Profile: Robust Financials: Debt free, cash in the bank until after completion of NASH trial 4 … With Significant Room for Valuation Upside NASH Peer Comparables 5 Strong Financial Position: • Ticker Code: IMC.AX (Australia) • Share price: (as at 22 October 2015) AUD$0.51; USD$0.37 • Shares outstanding: 75M • Market Cap: AUD$40M; USD$29M • Cash: (as of 30 June 2015) $3.1M • Debt: $0 6 PIPELINE Portfolio • IMM-124E (anti LPS + adjuvants) for NASH • IMM-529 for Clostridium Difficile 8 IMM-124E Compelling MOA in NASH NASH – Pathogenesis Gut flora imbalance Overgrowth of intestinal bacteria incl. gram-negative bacteria IMM-124E – MOA Obesity is associated with a chronic inflammatory state Causing: - Impaired gut epithelial integrity - Increased gut permeability - Increased LPS serum levels - Activation of innate immune cells in the gut Unique Properties - Increased concentration of immunoglobulin (mainly IgG) - Strong anti-LPS properties, Cross reactive - Immune-reactive adjuvants that promote regulatory T-Cells that suppress systemic inflammation - Not absorbed in the blood - Immune modulation without immune suppression 1 Drives: - Increased BT from lumen into liver through portal vein (70% of blood flow to liver) - Increased hepatic / systemic inflammatory response (e.g., TNF) - Induction of systemic inflammation by innate immune cells in the gut Systemic inflammation: Inflammatory cells and cytokines secreted systemically Liver damage contributing to progression of steatosis then NASH then onto fibrosis and eventually cirrhosis 2 Prevents bacteria spread: Binds and neutralizes wide range of LPS Alter the function of innate immune cells in the gut Allows lumen to rebuild integrity Decreasing BT / LPS levels resulting in decreased liver inflammation Adjuvants promote regulatory T cells systemically that suppress site inflammation Decrease systemic and local inflammation Decreases liver inflammation - Improves liver function 9 IMM-124E In NASH Fibrotic Liver IMM-124E Treated Liver IMM124E Mizrahi M. 2013, AASLD; Hepatology 751A 10 IMM-124E - Improves Inflammation and Fibrosis Markers Group A: Control Group A: Control Group B: Naïve anti LPS Group C: Treated Group D: Treated Group B: Naïve anti LPS Group D: Treated Group C: Treated Decreased Portal Inflammation Improved Metavir Fibrosis Score 3 4 3.4 2.4 3.5 2.5 3 2 2.5 1.4 1.33 1.5 1.8 2 0.66 1 1.5 1 1 0.5 *p<0.02 ^^ p<0.01 0 A B C D *p<0.0009 ^^ p<0.0003 0.5 0 0 A B C D Mizrahi M. 2013, AASLD; Hepatology 751A 11 IMM-124E Clinical Improves Liver Function and Insulin Resistance Results of a Phase I/IIA clinical trial; N=10 Improved Liver Enzymes Improved HBA1C, OGTT and HOMA Mizrahi M, J Inflamm Res. 2012;5:141-50 12 NASH – A $35B - $40B Market Major Commercial Opportunity • 25% of the US population has NAFLD • 5% of the population will develop NASH • No treatments approved • All major pharma looking to get into the game • Most treatments ‒ Do not capture the entire disease population ‒ Limited efficacy ‒ Severe / unknown side effect profile Estimated Market Size: $35B - $40B USD by 2025 (Deutsche Bank) 13 PORTFOLIO • IMM-124E (anti LPS + adjuvants) for NASH • IMM-529 for Clostridium Difficile 14 C-Difficile – A Significant Unmet Need Center for Disease Control (CDC) Antibiotic Resistance Threats in the United States, 2013 15 IMM-529 – Toxin B Vaccine Specially Developed to Defeat C-Diff - IMM-529 is combination vaccine that targets: Toxin B, C-Diff spores and C-Diff vegetative cells Murine studies performed at Monash University, Australia: - Prophylaxis – Demonstrating effectiveness in 80% of cases - Treatment – Prevented death in 80% of cases Prophylaxis Treatment 16 TRAVELAN® Stop it before it starts Travelan® A Unique Preventative Product The only therapy that prevents Travelers’ Diarrhea by up to 90% • Marketed in the US, Australia by Immuron and by Paladin/Endo in Canada • Global market estimate: US$ 600M - 1.2B • All-natural product; Without Travelan®: Bacteria attach to gut wall and infect With Travelan®: Bacteria neutralized by Travelan® antibodies • Clinically proven • SAFE • OTC • Strong brand loyalty • Multiple life-cycle opportunities 18 Travelan® Status 06/2015 Country Discussions Progress in 07/2015 – 06/2016 Term Sheet Licensed Regulatory In Market Canada South Korea Other Asian Countries United States India China * Regulatory application preceding partnering engagement 19 SUMMARY Investment Highlights Immuron Is a Compelling Investment Opportunity NASH and ASH: Two Phase II studies in progress with an increasingly alluring potential upside Travelan: Revenues growing and positioned to grow further with successful USA launch Pipeline: Progressing; potential for multi-billion $ assets Cap Profile: Robust Financials: Debt free, cash in the bank until after completion of NASH trial 21 Corporate Structure The Board and Management Dr Roger Aston Chairman Roger has more than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding Chief Executive Officer and a Director of Mayne Pharma Group Limited. Daniel Pollock Non-executive Director Daniel is an internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in overseas new market entries, distribution agreements and corporate start-ups. Stephen Anastasiou Non-executive Director Stephen has extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG. Thomas Liquard Chief Executive Officer Thomas spent the majority of his career at Pfizer in New York in various commercial positions and was COO then CEO of Alchemia Limited, an oncology ASX biotech company. Dan Peres, MD Head of Medical Dan had been leading Medical Device and Pharma companies in their clinical stage since 2008. a Physician in origin has years of experience in management and medical development. Jerry Kanellos, PhD COO & Scientific Officer Dr Jerry Kanellos has over 20 years of experience in the pharmaceutical and biotech industries including CMC, operations and business development. He has held senior roles at CSL and Transbio Limited. Neta Tobis Clinical Director With over 7 years’ experience of international trial management for small to large pharma and medical device companies as well as working within large CROs (PPD). Reza Moussakhani A professional Operations manager with extensive experience in implementation of project / quality and Manufacturing Quality Director process improvements including with Hospira and Sigma Pharmaceuticals. Dr. Yaron Ilan Medical and Scientific Advisor Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles. 22 THANK YOU